secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2026-08-10T11:40:52+00:00
Accession:  0001193125-26-341270
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz to acquire Actio Biosciences for $820M upfront, up to $500M milestones
---------------------------------------------------------------------------

- Jazz to acquire Actio Biosciences for $820M upfront plus up to $500M in approval/sales milestones.
- Lead asset ABS-1230: first-in-class KCNT1 inhibitor for KCNT1+ epilepsy, no FDA-approved therapies.
- ABS-1230 has FDA Fast Track, Rare Pediatric Disease, Orphan Drug designations; accepted into RDEP program.
- Transaction expected to close Q4 2026; funded via cash on hand and existing facilities.
- Actio spins out new entity with TRPV4 inhibitor ABS-0871; Jazz takes minority stake.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312526341270/0001193125-26-341270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312526341270/d106596d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-341270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer